OMAHA, Neb., May 26 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) today announced that Craig Tuttle, President and Chief Executive Officer, will make a presentation regarding the business strategy of the Company at the Noble Financial Sixth Annual Equity Conference on Tuesday, June 8 at 1:00 p.m. EDT. The conference will be held at the Hard Rock Hotel in Hollywood, Florida.
The presentation will be webcast and available for viewing through Noble Financial's website link: http://noble.mediasite.com/mediasite/viewer/?peid=e63c31f8a22848939184a4c87cae 9e22.
Transgenomic recommends registering at least 10 minutes prior to the start of the presentation to ensure timely access. The archived presentation will be available by logging onto the Company's Investor Relations web page at http://www.transgenomic.com/events.asp?id=6 and following the instructions. The written materials will be archived on the Company's website for 90 days following the event.
About Transgenomic, Inc.
Transgenomic, Inc. (http://www.transgenomic.com/ ) is a global biotechnology company specializing in high sensitivity genetic variation and mutation analysis, providing products and services in DNA mutation detection and discovery for clinical research, clinical molecular diagnostics and pharmacogenomics analyses. Its product offerings include the WAVE® Systems and associated consumables specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification. With broad applicability to genetic research, over 1,475 systems have been shipped to customers in more than 30 countries. The SURVEYOR® Mutation Detection Kits and SURVEYOR Check-It Kit provide reagents and protocols for high sensitivity detection of mutations in DNA. In addition, HANABI automated chromosome harvesting systems improve laboratory productivity with consistent quality compared with manual methods for cytogenetic analyses. Service offerings include the Transgenomic Molecular Laboratory, which provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases. Transgenomic Pharmacogenomics Services is a CRO for pharmacogenomic, translational research and clinical trials.
Transgenomic, Inc.
CONTACT: Debra Schneider, CFO of Transgenomic, Inc., +1-402-452-5400,
investorrelations@transgenomic.com; or Investor Relations, Kim Sutton
Golodetz, +1-212-838-3777, kgolodetz@lhai.com, or Bruce Voss, +1-310-691-7100,
bvoss@lhai.com, both of Lippert/Heilshorn & Associates, for Transgenomic,
Inc.
Web Site: http://www.transgenomic.com/
